Video

Dr. Eric Klein discusses how IsoPSA works for prostate cancer risk assessment

Author(s):

Urology Times staff

“IsoPSA is a way of measuring all the different PSA-related proteins in the blood,” says Eric A. Klein, MD.

In this video, Eric A. Klein, MD, provides an overview of the IsoPSA test and how it works. Klein is Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.

Related Videos
Sarah Razavi, MD, answers a question during a Zoom video interview
1 expert in this video
1 expert in this video
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Woman talking with a doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
Related Content
Study shows value of precision-based approaches in prostate cancer
May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke
The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke
Initial study results may be available as soon as the first half of 2026.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke
The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
© 2025 MJH Life Sciences

All rights reserved.